Lionel Adès
Adès, Lionel 1970-...
Adés, Lionel
VIAF ID: 7721019 (Personal)
Permalink: http://viaf.org/viaf/7721019
Preferred Forms
- 100 1 _ ‡a Adès, Lionel, ‡d 1970-....
- 200 _ | ‡a Adés ‡b Lionel
-
- 100 1 _ ‡a Adès, Lionel ‡d 1970-...
- 100 0 _ ‡a Lionel Adès
4xx's: Alternate Name Forms (3)
Works
Title | Sources |
---|---|
Are myelodysplastic syndromes and acute myeloid leukaemia occurring during the course of lymphoma always therapy related? | |
Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia | |
Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study. | |
Comparison of TP53 mutations screening by functional assay of separated allele in yeast and next-generation sequencing in myelodysplastic syndromes | |
Devenir des enfants atteints de leucémie aigüe promyélocytaire dans deux études françaises | |
Dual origin of relapses in retinoic-acid resistant acute promyelocytic leukemia. | |
Epstein-Barr virus (EBV) reactivation in allogeneic stem-cell transplantation: relationship between viral load, EBV-specific T-cell reconstitution and rituximab therapy. | |
Erlotinib antagonizes constitutive activation of SRC family kinases and mTOR in acute myeloid leukemia. | |
Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study | |
Exome analysis of treatment-related AML after APL suggests secondary evolution | |
Genetic analysis of therapy-related myeloid neoplasms occurring after intensive treatment for acute promyelocytic leukemia | |
Granulomonocytic progenitors are key target cells of azacytidine in higher risk myelodysplastic syndromes and acute myeloid leukemia | |
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes | |
A landscape of germline mutations in a cohort of inherited bone marrow failure patients. | |
Limited efficacy and tolerance of imatinib mesylate in steroid-refractory sclerodermatous chronic GVHD. | |
Localization of the NRAS:BCL-2 complex determines anti-apoptotic features associated with progressive disease in myelodysplastic syndromes | |
Long-term follow-up of European APL 2000 trial, evaluating the role of cytarabine combined with ATRA and Daunorubicin in the treatment of nonelderly APL patients | |
Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial. | |
A multiparametric niche-like drug screening platform in acute myeloid leukemia | |
mutation is not associated with prolonged complete remission in acute myeloid leukemia patients treated with hypomethylating agents | |
Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. | |
Prognostic impact of JAK2V617F mutation in myelodysplatic syndromes: A matched case control study | |
Prognostic score including gene mutations in chronic myelomonocytic leukemia. | |
The revised IPSS is a powerful tool to evaluate the outcome of MDS patients treated with azacitidine: the GFM experience | |
Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis | |
Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents | |
Slow relapse in acute myeloid leukemia with inv(16) or t(16;16). | |
Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial. | |
stoire de la thérapie ciblée en cancérologie [Multimédia multisupport] | |
syndromes myélodysplasiques de l'adulte | |
Tc1 clonal T cell expansion during chronic graft-versus-host disease-associated hypereosinophilia | |
TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups | |
Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM). | |
A variant erythroferrone disrupts iron homeostasis in SF3B1-mutated myelodysplastic syndrome | |
Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience | |
When can real-time quantitative RT-PCR effectively define molecular relapse in acute promyelocytic leukemia patients? (Results of the French Belgian Swiss APL Group). |